Tango details Phase 3 plans for pancreatic cancer combo, holds $977.5 millionNov 16Regulatory decisionKura Oncology, Inc.Summit TherapeuticsUpdated
Cullinan reports Q3 2026 results, flags December CLN-978 data and zipalertinib NDA progressNov 10Quarterly updateBlossomHill TherapeuticsCLN-978
FDA approves daraxonrasib as Elicio preps Phase 1 trial combining it with camupepimutNov 6Regulatory decisiondaraxonrasibElicio TherapeuticsUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Revolution Medicines' daraxonrasib appears in two new pancreatic cancer trial registrationsOct 27Weekly roundup, 2 itemsdaraxonrasibRevolution Medicines, Inc.
Tango reports 82% response rate for vopimetostat-daraxonrasib combo in pancreatic cancerOct 23Clinical readoutdaraxonrasibRevolution Medicines, Inc.
Revolution Medicines draws $250M loan tranche after FDA approves RASONQUEOct 13FinancingdaraxonrasibRevolution Medicines, Inc.
Veru advances oral sabizabulin toward Phase 2 in daraxonrasib-resistant pancreatic cancerSep 8Clinical readoutdaraxonrasibRevolution Medicines, Inc.
Revolution Medicines registers Phase 3 RASolute 309 in KRAS G12D pancreatic cancerSep 8Trial updatedaraxonrasibRevolution Medicines, Inc.
Johns Hopkins registers Phase 2 trial of Revolution Medicines' daraxonrasib in biliary tract cancerAug 28Trial updatedaraxonrasibRevolution Medicines, Inc.
Tango reports Phase 1/2 pancreatic cancer data, eyes Phase 3 as it posts Q2 2026 resultsAug 11Quarterly updateTango Therapeutics, Inc.
Tango Therapeutics files new $400 million at-the-market equity offering with Leerink PartnersAug 11FinancingTango Therapeutics, Inc.
Synnovation registers Phase 1 trial of SNV1521 with Revolution Medicines' daraxonrasibAug 10Trial updatedaraxonrasibRevolution Medicines, Inc.
Royalty Pharma raises 2026 guidance after 14% Royalty Receipts growth in Q2Aug 5Quarterly updateRoyalty Pharma plc
Revolution Medicines advances daraxonrasib NDA and reports new lung cancer combination dataAug 5Quarterly updatedaraxonrasibRevolution Medicines, Inc.
Nuvectis reports Q2 2026 results as ciprocopan wins first China approvalAug 4Quarterly updateNuvectis Pharma, Inc.